CStone Pharmaceuticals

12/11/2019 | Press release | Distributed by Public on 12/11/2019 06:01

VOLUNTARY ANNOUNCEMENT - CSTONE COMPLETES REGISTRATION FILING FOR THE PHASE I TRIAL OF ITS TUMOR IMMUNE MICROENVIRONMENT MODULATOR CS3005 TO ENABLE STUDY INITIATION IN AUSTRALIA